Group 1 - The China Securities Regulatory Commission has issued a notice regarding Jiangsu Ruike Biotechnology Co., Ltd.'s application for the conversion of 141,953,489 shares from domestic unlisted to overseas listed shares for trading on the Hong Kong Stock Exchange [1][4][5] - The shareholders involved in this conversion include various investment partnerships and funds, with significant contributions from entities such as Taizhou Yuangong Technology Partnership and Springleaf Investments Pte. Ltd. [4][5] Group 2 - Ruike Biotechnology has recently had its new drug application for the recombinant herpes zoster vaccine REC610 accepted by the National Medical Products Administration, which utilizes the company's self-developed BFA01 adjuvant [3] - Currently, the only other recombinant herpes zoster vaccine available globally is GlaxoSmithKline's Shingrix, indicating a competitive landscape for Ruike's new product [3]

Group 1 - The China Securities Regulatory Commission has issued a notice regarding Jiangsu Ruike Biotechnology Co., Ltd.'s application for the conversion of 141,953,489 shares from domestic unlisted to overseas listed shares for trading on the Hong Kong Stock Exchange [1][4][5] - The shareholders involved in this conversion include various investment partnerships and funds, with significant holdings from entities such as Taizhou Yuangong Technology Partnership and Springleaf Investments Pte. Ltd. [4][5] Group 2 - Ruike Biotechnology has recently had its new drug application for the recombinant herpes zoster vaccine REC610 accepted by the National Medical Products Administration, which utilizes a novel adjuvant BFA01 developed by the company [3] - Currently, the only other recombinant herpes zoster vaccine available globally is GlaxoSmithKline's Shingrix [3]

Investment Rating - The industry investment rating is maintained at "Overweight" [1] Core Views - The vaccine industry is experiencing steady growth, with 68 preventive vaccines approved for clinical trials in 2025, an increase of 13 from 2024 [3] - The industry is transitioning from scale expansion to innovation-driven growth, facing short-term challenges due to supply-demand imbalances and homogenized competition, but the long-term outlook remains positive [9][24] - Key drivers for the industry's development include policy support, increasing demand due to aging populations, and technological innovation [9][26] Summary by Sections Industry Dynamics - The approval of new vaccines is on the rise, with significant advancements in innovative vaccines and multi-valent products [3] - The market is characterized by a high proportion of Me-too products, leading to intense competition and price declines [8] Market Performance - The vaccine sector has seen a cumulative decline of 12.35% since the beginning of 2025, with a recent weekly drop of 2.52% [4][14] - Companies such as Olin Bio, Hualan Biological, and CanSino have shown better performance, while companies like Gendik and Wantai Biologics have lagged [5] Valuation Metrics - The vaccine sector's PE (ttm) is 90.01X, down 2.34X from the previous period, while the PB (lf) stands at 1.74X, reflecting a slight decrease [6] Investment Recommendations - The industry is advised to focus on companies with strong R&D capabilities and differentiated product lines, particularly those with high technical barriers [9][26] - Companies like CanSino and Kanghua Biological are recommended due to their innovative strengths and market demand resilience [9][26]

Core Viewpoint - The company has received formal acceptance from the National Medical Products Administration for the new drug application of its adjuvanted recombinant shingles vaccine REC610, indicating progress in its development and potential market entry [1]. Group 1: Vaccine Development - REC610's new drug application has been officially accepted with acceptance number CXSS2500145 [1]. - The vaccine targets shingles, a common disease caused by latent viral infection, which affects approximately 6 million people annually in China, with a trend of younger patients [1]. - REC610 utilizes the company's proprietary adjuvant BFA01, which enhances the immune response by promoting high levels of VZV glycoprotein E (gE) specific CD4+ T cells and antibodies [1]. Group 2: Clinical Trials - REC610 received approval for clinical trials in October 2023, with the completion of all participant enrollments for Phase III trials expected by December 2024 [2]. - The clinical study is designed as randomized, double-blind, and placebo-controlled, focusing on the vaccine's efficacy, safety, and immunogenicity in healthy participants aged 40 and above [2]. - Previous exploratory clinical studies in the Philippines and China, using Shingrix® as a positive control, showed that REC610 has good overall safety and induces strong gE-specific immune responses comparable to Shingrix® [2].

Core Viewpoint - The company has received formal acceptance from the National Medical Products Administration for the new drug application of its adjuvanted recombinant herpes zoster vaccine REC610, indicating progress in its development and potential market entry [1]. Group 1: Vaccine Development - REC610's new drug application has been officially accepted with acceptance number CXSS2500145 [1]. - The vaccine targets herpes zoster, a common disease affecting approximately 6 million people annually in China, with a trend of increasing incidence among younger populations [1]. - REC610 utilizes the company's self-developed BFA01 adjuvant, which enhances the immune response by promoting high levels of VZV glycoprotein E (gE) specific CD4+ T cells and antibodies [1]. Group 2: Clinical Trials - REC610 received approval for clinical trials in October 2023, with the completion of participant enrollment for Phase III trials expected by December 2024 [2]. - The clinical study is designed as a randomized, double-blind, placebo-controlled trial to evaluate the vaccine's efficacy, safety, and immunogenicity in healthy participants aged 40 and above [2]. - Previous exploratory clinical studies in the Philippines and China, using Shingrix as a positive control, showed that REC610 has good overall safety and induces strong gE-specific immune responses comparable to Shingrix [2].

Core Viewpoint - The company has received formal acceptance from the National Medical Products Administration for the new drug application of its adjuvanted recombinant shingles vaccine REC610, indicating progress in its development and potential market entry [1] Group 1: Vaccine Development - REC610's new drug application acceptance number is CXSS2500145, marking a significant milestone for the company [1] - The vaccine targets shingles, a common disease caused by latent viral infection, which affects approximately 6 million people annually in China, with a trend of younger patients being affected [1] - REC610 utilizes the company's self-developed BFA01 adjuvant, which enhances the immune response by promoting high levels of VZV glycoprotein E (gE) specific CD4+ T cells and antibodies [1] Group 2: Clinical Trials - REC610 received a clinical trial approval notice from the National Medical Products Administration in October 2023, with the notice number 2023LP02151 [2] - The Phase III clinical trial is set to complete enrollment of all participants by December 2024, and is currently following the clinical protocol for subsequent observational visits [2] - The clinical study is designed as a randomized, double-blind, placebo-controlled trial to evaluate the vaccine's efficacy, safety, and immunogenicity in healthy participants aged 40 and above [2]